ArticleDiscover oncology2025
NCAPD3 is involved in papillary thyroid carcinoma proliferation, metastasis, and aerobic glycolytic pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucose Metabolic Reprogramming in Thyroid Cancer: Underlying Molecular Mechanisms and Links to Progression and Treatment.Current medical science · 2026Review
- Knockdown of TRIM35 suppresses cell proliferation and metastasis by modulating the PPAR signalling pathway in papillary thyroid cancer cells.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the expression of non-SMC condensin II complex subunit D3 (NCAPD3) in papillary thyroid carcinoma (PTC) tissues, assess its impact on the growth and metastatic potential of PTC cells, and investigate its role in regulating glycolysis to uncover the underlying mechanisms involved.
methodsNCAPD3 levels in PTC tissues were detected using immunohistochemistry. siRNA transfection was used to silence NCAPD3 in K1 and TPC-1 cells. Cell proliferation rates were detected using the Cell Counting Kit-8 assay, migration rates were evaluated using wound healing and Transwell cell migration assays, and invasion rates were assessed using the Transwell-Matrigel cell invasion assay. Moreover, the aerobic glycolysis-related factors lactate, lactate dehydrogenase A (LDHA), and pyruvate kinase M2 (PKM2) were detected using kits.
resultsNCAPD3 was highly expressed in PTC tissues. Its expression showed no significant association with patient age, gender, or lymphocytic thyroiditis but was significantly correlated with larger tumor size and lymphovascular invasion. NCAPD3 expression significantly decreased in K1 and TPC-1 cells after transfection with siRNA. Low NCAPD3 expression reduced the proliferation rate of K1 and TPC-1 cells and inhibited cell migration and invasion. Moreover, NCAPD3 silencing decreased LDHA, PKM2, and lactate levels.
conclusionsNCAPD3 was highly expressed in PTC tissues, and correlated with aggressive features (tumor size and lymphovascular invasion). NCAPD3 silencing inhibited proliferation, migration, invasion, and aerobic glycolysis of PTC cells. Therefore, NCAPD3 may serve as a potential therapeutic target for PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.